WO2014113820A1 - Inhibiteurs d'un récepteur des œstrogènes - Google Patents

Inhibiteurs d'un récepteur des œstrogènes Download PDF

Info

Publication number
WO2014113820A1
WO2014113820A1 PCT/US2014/012405 US2014012405W WO2014113820A1 WO 2014113820 A1 WO2014113820 A1 WO 2014113820A1 US 2014012405 W US2014012405 W US 2014012405W WO 2014113820 A1 WO2014113820 A1 WO 2014113820A1
Authority
WO
WIPO (PCT)
Prior art keywords
era
cells
bhpi
upr
positive
Prior art date
Application number
PCT/US2014/012405
Other languages
English (en)
Inventor
David J. Shapiro
Neal D. ANDRUSKA
Mathew M. CHERIAN
Lily MAHAPATRA
Mao CHENGJIAN
William HELFERICH
Xujuan YANG
Original Assignee
Shapiro David J
Andruska Neal D
Cherian Mathew M
Mahapatra Lily
Chengjian Mao
Helferich William
Yang Xujuan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shapiro David J, Andruska Neal D, Cherian Mathew M, Mahapatra Lily, Chengjian Mao, Helferich William, Yang Xujuan filed Critical Shapiro David J
Priority to CA2898732A priority Critical patent/CA2898732A1/fr
Priority to EP14740515.3A priority patent/EP2945646A4/fr
Priority to AU2014207272A priority patent/AU2014207272A1/en
Publication of WO2014113820A1 publication Critical patent/WO2014113820A1/fr
Priority to IL240019A priority patent/IL240019A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une méthode de traitement d'un cancer positif pour ERα, comprenant l'administration à un patient en ayant besoin d'une quantité efficace d'un inhibiteur à petites molécules ou d'un sel pharmaceutiquement acceptable de celui-ci, l'inhibiteur à petites molécules agissant par l'intermédiaire du récepteur α des œstrogènes et active un ou plusieurs des trois bras de la voie de réponse de la protéine non repliée (UPR).
PCT/US2014/012405 2013-01-18 2014-01-21 Inhibiteurs d'un récepteur des œstrogènes WO2014113820A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA2898732A CA2898732A1 (fr) 2013-01-18 2014-01-21 Inhibiteurs d'un recepteur des ƒstrogenes
EP14740515.3A EP2945646A4 (fr) 2013-01-18 2014-01-21 Inhibiteurs d'un récepteur des strogènes
AU2014207272A AU2014207272A1 (en) 2013-01-18 2014-01-21 Estrogen receptor inhibitors
IL240019A IL240019A0 (en) 2013-01-18 2015-07-19 Estrogen receptor inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361754292P 2013-01-18 2013-01-18
US61/754,292 2013-01-18

Publications (1)

Publication Number Publication Date
WO2014113820A1 true WO2014113820A1 (fr) 2014-07-24

Family

ID=51210145

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/012405 WO2014113820A1 (fr) 2013-01-18 2014-01-21 Inhibiteurs d'un récepteur des œstrogènes

Country Status (5)

Country Link
EP (1) EP2945646A4 (fr)
AU (1) AU2014207272A1 (fr)
CA (1) CA2898732A1 (fr)
IL (1) IL240019A0 (fr)
WO (1) WO2014113820A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107164519A (zh) * 2017-06-26 2017-09-15 深圳优圣康医学检验所有限公司 一种基于荧光pcr检测esr1基因突变的引物及探针
WO2020009958A1 (fr) * 2018-07-03 2020-01-09 The Board Of Trustees Of The University Of Illinois Activateurs de la réponse à une protéine non dépliée
WO2021222738A1 (fr) * 2020-05-01 2021-11-04 The Board Of Trustees Of The University Of Illinois Composés pour cancers positifs au récepteur des oestrogènes
CN113720823A (zh) * 2021-05-17 2021-11-30 丹望医疗科技(上海)有限公司 检测类器官最大截面积的方法及其应用
WO2022032146A1 (fr) * 2020-08-07 2022-02-10 Systems Oncology, Llc Procédés d'inhibition de la croissance de cancers era positifs

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2022356A1 (fr) * 1990-07-31 1992-02-01 David J. Shapiro Methode et matieres pour la production de proteines
US20070099976A1 (en) * 2004-02-13 2007-05-03 President And Fellows Of Harvard College 3-3-di-substituted-oxindoles as inhibitors of translation initiation
WO2011044548A1 (fr) * 2009-10-09 2011-04-14 The Ohio State University Research Foundation Agents mimétiques de restriction énergétique de thiazolidinédione

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES426436A1 (es) * 1974-05-18 1976-07-01 Andreu Sa Dr Procedimiento para la obtencion de derivados de la 3,3-bis (4-hidroxifenil)-2-indolinona.
KR20060130781A (ko) * 2004-04-08 2006-12-19 토포타겟 에이/에스 다이페닐 인돌-2-온 화합물 및 암 치료에 있어서의 그의용도

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2022356A1 (fr) * 1990-07-31 1992-02-01 David J. Shapiro Methode et matieres pour la production de proteines
US20070099976A1 (en) * 2004-02-13 2007-05-03 President And Fellows Of Harvard College 3-3-di-substituted-oxindoles as inhibitors of translation initiation
WO2011044548A1 (fr) * 2009-10-09 2011-04-14 The Ohio State University Research Foundation Agents mimétiques de restriction énergétique de thiazolidinédione

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP2945646A4 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107164519A (zh) * 2017-06-26 2017-09-15 深圳优圣康医学检验所有限公司 一种基于荧光pcr检测esr1基因突变的引物及探针
WO2020009958A1 (fr) * 2018-07-03 2020-01-09 The Board Of Trustees Of The University Of Illinois Activateurs de la réponse à une protéine non dépliée
US11046647B2 (en) 2018-07-03 2021-06-29 The Board Of Trustees Of The University Of Illinois Activators of the unfolded protein response
EP3817741A4 (fr) * 2018-07-03 2022-07-06 The Board of Trustees of the University of Illinois Activateurs de la réponse à une protéine non dépliée
US11584718B2 (en) 2018-07-03 2023-02-21 The Board Of Trustees Of The University Of Illinois Activators of the unfolded protein response
WO2021222738A1 (fr) * 2020-05-01 2021-11-04 The Board Of Trustees Of The University Of Illinois Composés pour cancers positifs au récepteur des oestrogènes
WO2022032146A1 (fr) * 2020-08-07 2022-02-10 Systems Oncology, Llc Procédés d'inhibition de la croissance de cancers era positifs
CN113720823A (zh) * 2021-05-17 2021-11-30 丹望医疗科技(上海)有限公司 检测类器官最大截面积的方法及其应用

Also Published As

Publication number Publication date
EP2945646A4 (fr) 2016-09-21
AU2014207272A1 (en) 2015-07-30
EP2945646A1 (fr) 2015-11-25
CA2898732A1 (fr) 2014-07-24
IL240019A0 (en) 2015-09-24

Similar Documents

Publication Publication Date Title
JP7323592B2 (ja) 癌を治療するための併用療法
Xie et al. Atg7 overcomes senescence and promotes growth of Braf V600E-driven melanoma
Cao et al. Narciclasine induces autophagy‐dependent apoptosis in triple‐negative breast cancer cells by regulating the AMPK‐ULK1 axis
CA2803446C (fr) Utilisation des antagonistes plk4 destines au traitement de maladies attribuables a la mutation du gene pten
CN108135177A (zh) 用于治疗癌症的方法
US20160015693A1 (en) Methods and compounds for preventing and treating a tumour
CA3180314A1 (fr) Methodes de traitement du cancer chez des patients ayant un gene kras anormal ou des deletions dans le chromosome 9
WO2014113820A1 (fr) Inhibiteurs d'un récepteur des œstrogènes
Ha et al. Novel pharmacological modulators of autophagy: an updated patent review (2012-2015)
Wang et al. Dopamine suppresses osteoclast differentiation via cAMP/PKA/CREB pathway
Huang et al. Characterization of the biological activity of a potent small molecule Hec1 inhibitor TAI-1
JP2015525063A (ja) 低酸素状態に基づくｈｓｐ９０インヒビターでの治療のための被験者の予備選択
WO2017223433A1 (fr) Méthodes et compositions pour le traitement du cancer
WO2019165473A1 (fr) Procédés de traitement du cancer comprenant des inhibiteurs de cdc7
Liu et al. Activation of SIK1 by phanginin A inhibits hepatic gluconeogenesis by increasing PDE4 activity and suppressing the cAMP signaling pathway
US9802948B2 (en) Inhibitors of late SV40 factor (LSF) as cancer chemotherapeutics
US9815845B2 (en) Inhibitors of late SV40 factor (LSF) as cancer chemotherapeutics
KR20210060642A (ko) 성장 관련 질환 및/또는 그것의 임상적 상태를 억제 및/또는 치료하기 위한 조성물 및 방법
Schaf et al. Enhanced Sestrin expression through Tanshinone 2A treatment improves PI3K-dependent inhibition of glioma growth
EP2821071A1 (fr) Composés pour le traitement du cancer du sein
US20230158034A1 (en) Co-treatment with cdk4/6 and cdk2 inhibitors to suppress tumor adaptation to cdk2 inhibitors
Williams et al. Enhanced Sestrin expression through Tanshinone 2A treatment improves PI3K-dependent inhibition of glioma growth
de Oliveira SIRT1 and mTor Interplay as an Arising Therapeutic Target for Bladder Cancer.
JP2023530734A (ja) アイソフォーム特異的アルデヒドデヒドロゲナーゼ阻害剤
Pepermans Identification of a Novel Class of ER-Selective Ligands Lacking Cross-reactivity to GPER

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14740515

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2014740515

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 240019

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2898732

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2014207272

Country of ref document: AU

Date of ref document: 20140121

Kind code of ref document: A